Search results
14 lip 2021 · Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked. The recommendations also apply to biosimilar products of the technologies that have a marketing authorisation allowing the use of the biosimilar for the ...
The diagnosis of rheumatoid arthritis (RA) divides into two overarching types: seropositive and seronegative. Seropositive is the most common diagnosis among RA patients. Being seropositive means that your blood tests show the presence of antibodies that are hypothesized to cause symptoms of RA.
23 sty 2021 · R4RA is the first biopsy-driven, multicentre, randomised trial comparing tocilizumab with rituximab in patients with rheumatoid arthritis who had inadequate responses to anti-TNF drugs stratified for synovial B-cell status.
Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease characterised by inflamed joints and bone damage. As with any disease RA has a series of events leading up to its diagnosis. There are six phases that a patient can experience throughout the development of RA.
Discussion. This phase 2a study was the first to evaluate the efficacy, safety, PK and PD of an anti-FcRn monoclonal antibody, nipocalimab and its effect on disease-related biomarkers in participants with seropositive RA and an inadequate response or intolerance to anti-TNF agents.
Rheumatoid arthritis is a long-term condition that causes pain, swelling and stiffness in the joints. The condition usually affects the hands, feet and wrists. There may be periods where symptoms become worse, known as flare-ups or flares.
Biologic medicines for the treatment of rheumatoid arthritis (RA) are made from proteins produced by genetically-engineered cells grown in a laboratory. They work by blocking the activity of a key chemical messenger involved in inflammation that gives rise to joint swelling and other symptoms.
